Fig. 7From: Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patientsGenomic profiling of enrolled subjects. Genomic profiling was performed by next-generation sequencing with a 450 cancer-related gene panel on both FFPE tumor and paired peripheral blood samples from 23 available subjects. Genomic alterations including SNV, short and long INDELs, CNV, and gene rearrangement and fusions were assessedBack to article page